The FDA says the nationwide shortage for Ozempic and Wegovy is over, but as CBS News New York's Ali Bauman explains, that supply change could lead to consumers paying more.
The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback